BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014; 6(12): 860-869 [PMID: 25544873 DOI: 10.4254/wjh.v6.i12.860] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Wen X, Su H, Wang Y, Pu Z, Gao J, Ji Z, Yuan X, Li X, Zhang W, Zhang L, Long Y, Yan Y, Shao Z. Prevalence and natural course of occult hepatitis B virus infection in residents of 2 communities of Wuwei City, Gansu Province, China. J Viral Hepat 2018;25:281-8. [DOI: 10.1111/jvh.12805] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Costa JEF, Morais VMS, Gonçales JP, Medeiros AADP, Barroso H, Compri AP, Fukasawa L, Moreira RC, Coêlho MRCD. Occult hepatitis B virus infection in patients with leprosy. J Med Virol 2019;91:775-80. [PMID: 30512182 DOI: 10.1002/jmv.25374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Almeida RW, Mello FCDA, Menegoy IV, Santo MPDE, Ginuíno CF, Sousa PSF, Villar LM, Lampe E, Lewis-Ximenez LL. Detection and molecular characterisation of a diagnosis escape variant associated with occult hepatitis B virus in Brazil. Mem Inst Oswaldo Cruz 2017;112:485-91. [PMID: 28591309 DOI: 10.1590/0074-02760160477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Carimo AA, Gudo ES, Maueia C, Mabunda N, Chambal L, Vubil A, Flora A, Antunes F, Bhatt N. First report of occult hepatitis B infection among ART naïve HIV seropositive individuals in Maputo, Mozambique. PLoS One 2018;13:e0190775. [PMID: 29320552 DOI: 10.1371/journal.pone.0190775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Seed CR, Kiely P, Hoad VC, Keller AJ. Refining the risk estimate for transfusion-transmission of occult hepatitis B virus. Vox Sang 2017;112:3-8. [PMID: 27564651 DOI: 10.1111/vox.12446] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
6 Hyun CS, Lee S, Ventura WR. The prevalence and significance of isolated hepatitis B core antibody (anti-HBc) in endemic population. BMC Res Notes 2019;12:251. [PMID: 31060623 DOI: 10.1186/s13104-019-4287-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Oliveira MP, Matos MA, Silva ÁM, Lopes CL, Teles SA, Matos MA, Spitz N, Araujo NM, Mota RM, Kerr LR, Martins RM. Prevalence, Risk Behaviors, and Virological Characteristics of Hepatitis B Virus Infection in a Group of Men Who Have Sex with Men in Brazil: Results from a Respondent-Driven Sampling Survey. PLoS One 2016;11:e0160916. [PMID: 27508385 DOI: 10.1371/journal.pone.0160916] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Masrour-Roudsari J, Ebrahimpour S. Causal role of infectious agents in cancer: An overview. Caspian J Intern Med 2017;8:153-8. [PMID: 28932365 DOI: 10.22088/cjim.8.3.153] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
9 Mitsumoto-Kaseida F, Murata M, Takayama K, Toyoda K, Ogawa E, Furusyo N, Hayashi J. Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients. J Infect Chemother 2020;26:28-32. [PMID: 31279522 DOI: 10.1016/j.jiac.2019.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Diop M, Cisse-Diallo VMP, Ka D, Lakhe NA, Diallo-Mbaye K, Massaly A, Dièye A, Fall NM, Badiane AS, Thioub D, Fortes-Déguénonvo L, Lo G, Diop CT, Ndour CT, Soumaré M, Seydi M. [Occult hepatitis B reactivation in a patient with homozygous sickle cell disease: clinical case and literature review]. Pan Afr Med J 2017;28:127. [PMID: 29515745 DOI: 10.11604/pamj.2017.28.127.13640] [Reference Citation Analysis]
11 Liao H, Liu Y, Chen J, Ding W, Li X, Xu Z, Yang Y, Chen R, Si L, Xu X, Guo J, Xu D. Characterization of hepatitis B virus (HBV) preS/S gene mutations in blood donors with occult HBV infection in the Baoji area of North China: HBV PRES/S GENE MUTATIONS IN OBI BLOOD DONORS. Transfusion 2017;57:857-66. [DOI: 10.1111/trf.14046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
12 Ozoya OO, Chavez J, Sokol L, Dalia S. Optimizing antiviral agents for hepatitis B management in malignant lymphomas. Ann Transl Med 2017;5:39. [PMID: 28251118 DOI: 10.21037/atm.2016.12.25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Matsuda H, Hiramatsu K, Akazawa Y, Nosaka T, Saito Y, Ozaki Y, Hayama R, Takahashi K, Naito T, Ofuji K, Ohtani M, Nemoto T, Hida Y, Kimura H, Soya Y, Nakamoto Y. Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents. J Med Virol 2018;90:712-20. [PMID: 29283185 DOI: 10.1002/jmv.25011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Maraolo AE, Gentile I, Buonomo AR, Pinchera B, Borgia G. Current evidence on the management of hepatitis B in pregnancy. World J Hepatol 2018; 10(9): 585-594 [PMID: 30310536 DOI: 10.4254/wjh.v10.i9.585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Akram A, Islam SMR, Munshi SU, Tabassum S. Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay. J Viral Hepat 2018;25:1306-11. [DOI: 10.1111/jvh.12931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lee JY, Lim SH, Lee MY, Kim H, Sinn DH, Gwak GY, Choi MS, Lee JH, Jung CW, Jang JH, Kim WS, Kim SJ, Kim K. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver Int. 2015;35:2363-2369. [PMID: 25832927 DOI: 10.1111/liv.12838] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
17 Wang H, Wang M, Huang J, Xu R, Liao Q, Shan Z, Zheng Y, Rong X, Tang X, Li T, Wang W, Li C, Fu Y. Novel hepatitis B virus surface antigen mutations associated with occult genotype B hepatitis B virus infection affect HBsAg detection. J Viral Hepat 2020;27:915-21. [PMID: 32336003 DOI: 10.1111/jvh.13309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Azarkar Z, Ziaee M, Ebrahimzadeh A, Sharifzadeh G, Javanmard D. Epidemiology, risk factors, and molecular characterization of occult hepatitis B infection among anti-hepatitis B core antigen alone subjects. J Med Virol 2019;91:615-22. [PMID: 30345529 DOI: 10.1002/jmv.25343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Javanmard D, Namaei MH, Farahmand M, Ziaee A, Amini E, Ziaee M. Molecular and serological characterization of occult hepatitis B virus infection among patients with hemophilia. J Med Virol 2019;91:1519-27. [PMID: 30908666 DOI: 10.1002/jmv.25470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zamor PJ, Lane AM. Interpretation of HBV Serologies. Clin Liver Dis 2021;25:689-709. [PMID: 34593148 DOI: 10.1016/j.cld.2021.06.012] [Reference Citation Analysis]
21 Borojevic B, Chauhan A, Patterson S. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma. BMJ Case Rep 2021;14:e243526. [PMID: 34244190 DOI: 10.1136/bcr-2021-243526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mo X, Xu X, Ren Z, Guan J, Peng J. Patients with tuberculous meningitis and hepatitis B co-infection have increased risk for antituberculosis drug-induced liver injury and poor outcomes. Infect Dis (Lond) 2020;52:793-800. [PMID: 32619380 DOI: 10.1080/23744235.2020.1788223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
24 Jourdain G, Ngo-Giang-Huong N, Khamduang W. Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications. Infect Drug Resist 2019;12:977-87. [PMID: 31118703 DOI: 10.2147/IDR.S171695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Pondé RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015;34:1709-1731. [PMID: 26105620 DOI: 10.1007/s10096-015-2422-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
26 Wu SS, Shan QY, Xie WX, Chen B, Huang Y, Guo Y, Xie XY, Lu MD, Peng BG, Kuang M, Shen SL, Wang W. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma. Clin Transl Oncol 2020;22:401-10. [PMID: 31172445 DOI: 10.1007/s12094-019-02141-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Ozaras R, Mete B, Tabak F. Occult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2017;15:605. [PMID: 27923721 DOI: 10.1016/j.cgh.2016.11.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
28 Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms 2020;8:E1819. [PMID: 33218205 DOI: 10.3390/microorganisms8111819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Bal T, Onlen Y. The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy. Arab J Gastroenterol 2018;19:33-6. [PMID: 29503077 DOI: 10.1016/j.ajg.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Amer F, Yousif MM, Mohtady H, Khattab RA, Karagoz E, Ayaz KFM, Hammad NM. Surveillance and impact of occult hepatitis B virus, SEN virus, and torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection. Int J Infect Dis 2020;92:13-8. [PMID: 31863879 DOI: 10.1016/j.ijid.2019.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
32 Alshayea AI, Eid GE, El-Hazmi MM, Alhetheel AF. Prevalence and characterization of occult hepatitis B infection among blood donors in central Saudi Arabia. Saudi Med J 2016;37:1114-9. [PMID: 27652363 DOI: 10.15537/smj.2016.10.14708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Kengne M, Medja YFO, Tedom, Nwobegahay JM. [Residual risk for transfusion-transmitted hepatitis B virus infection due to occult hepatitis B virus infection in donors living in Yaoundé, Cameroon]. Pan Afr Med J 2021;39:175. [PMID: 34584601 DOI: 10.11604/pamj.2021.39.175.22365] [Reference Citation Analysis]
34 Samiee S, Kanavi MR, Javadi MA, Bagheri A, Balagholi S, Hashemi MS. Real Time Polymerase Chain Reaction for Hepatitis B Screening in Donor Corneas in the Central Eye Bank of Iran. J Ophthalmic Vis Res 2018;13:392-6. [PMID: 30479707 DOI: 10.4103/jovr.jovr_157_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Hu LP, Liu DP, Chen QY, Harrison TJ, He X, Wang XY, Li H, Tan C, Yang QL, Li KW, Fang ZL. Occult HBV Infection May Be Transmitted through Close Contact and Manifest as an Overt Infection. PLoS One 2015;10:e0138552. [PMID: 26457811 DOI: 10.1371/journal.pone.0138552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
36 Goyal A, Chauhan R. The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection. J Theor Biol 2018;455:269-80. [PMID: 29969598 DOI: 10.1016/j.jtbi.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
37 Varaklioti A, Kouramba A, Ioannidou P, Katsarou O. Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders. Infect Genet Evol 2017;54:397-401. [PMID: 28705716 DOI: 10.1016/j.meegid.2017.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Moraes TC, Fiaccadori FS, Souza M, Almeida TN, Cunha Mdos P, Castro Íde A, Cardoso Dd. Hepatitis B virus infection among institutionalized mentally ill patients in Brazil. Braz J Infect Dis 2015;19:643-7. [PMID: 26361836 DOI: 10.1016/j.bjid.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Samardžija M, Drenjančević D, Miletić M, Slavulj B, Jukić I, Zibar L, Mihaljević S, Ferenac Kiš M, Samardžija M. THE IMPACT OF POSITIVE ANTI-HBC MARKER ON PERMANENT DEFERRAL OF VOLUNTARY BLOOD DONORS IN EASTERN CROATIA AND ESTIMATION OF OCCULT HEPATITIS B VIRUS INFECTION RATE. Acta Clin Croat 2020;59:126-34. [PMID: 32724283 DOI: 10.20471/acc.2020.59.01.15] [Reference Citation Analysis]
40 Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med 2017;56:1967-71. [PMID: 28768965 DOI: 10.2169/internalmedicine.56.8233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
41 Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing. Transfus Med Hemother 2017;44:263-72. [PMID: 28924431 DOI: 10.1159/000460301] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
42 Trigo C, do Brasil PE, Costa MJ, de Castro L. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment. J Viral Hepat. 2016;. [PMID: 27624908 DOI: 10.1111/jvh.12583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]